Gastric carcinogenesis is am ultistepp rocess,d uring which numerous genetica nd epigenetica lterations accumulate: there are abnormalities of growth factors/receptors, angiogenic factors,c ell cycle regulators, DNA mismatch repair genes etc. These abnormalitiesdefine, at the same time, the biological character of the cancer cell and may thus serve as therapeutic targets. Genetic instability may cause accumulation of genetica bnormalities. The most important epigenetic alterations are DNA methylation, histone modification and chromatin remodeling. Some of these changes are common in gastric cancer,regardless of subtype, and some differ by histological type or (gastric or intestinal) mucinphenotype.Geneticpolymorphism is acrucialendogenouscause andfundamental aspect of cancer risk. Importantly,genetic polymorphisms are also associated with the therapeutic efficacy and toxicity of anti-cancer drugs. Genomic science and technology sucha sS erial Analysis of Gene Expression (SAGE) allows the identification of novel genes and molecules specifically up-regulatedordown-regulated in gastric cancer, e.g., RegIV and claudin-18 can be identified. Advances in our understandingo ft he genetic and molecular bases lead to improved diagnosis, personalised medicine and preventionofgastric cancer.
INTRODUCTION
Gastric cancer is one of the mostc ommon human cancers worldwide. Althoughr ecent diagnostic and therapeutic advances have providede xcellent survival for patients with early gastric cancer,the prognosis of patients with advanced cancer is still poor. The pathogenesis of gastric cancer involves Helicobacter pylori ( H. pylori)i nfection, chronic active or atrophic gastritis and intestinal metaplasia. Integrated research in molecular pathology has shown that gastric cancer is achronic proliferative disease characterised by multiple genetic and epigenetic alterations, i.e., ad isease of altered gene expression (1-5). Genetic polymorphism is an important endogenous cause and amodulator of the risk of aperson of developing gastric cancer. Advances of genomic science, including global analysis of gene expression, have uncovered detailed molecular mechanismsofgastric carcinogenesis (5, 6). Ab etter understanding of the molecular bases of gastric cancer may lead to new diagnostic, therapeuticand preventive approaches to the disease. Recently identified molecules that participate in carcinogenesis appear to be useful targets for cancertherapy.
This review describes an outline of the molecular pathway of stomach carcinogenesis, of the importance of epigenetica lterations, of the significance of genetic polymorphism, and of the biological and clinical roles of recently identified genes involved in gastriccancer.
OUTLINE OF MOLECULAR CARCINOGENESIS
An accumulation of genetic and molecular abnormalities occurs during gastric carcinogenesis, which is amultistep process (Fig. 1) (2, 4) . The steps include activation of oncogenes;o verexpression of growth factors/receptors and matrix metalloproteinases; inactivation of tumour suppressor genes, DNA repair genes and cell adhesion molecules; and abnormalities of cell cycle regulators that define biological characteristicso fc ancer cells (and could thus serve as therapeutic targets). Common genetic alterations in gastric canceri nclude loss of heterozygosity and point mutations of tumour suppressor genes, while common epigenetic changes aregene silencingoftumour suppressors by CpG island methylation and overexpression of tumour promoting genes at the transcriptional level. Genetic polymorphismsp redispose to cancer and alter the person's susceptibilitytocancer. Genetic instability,DNA methylation, telomerase activation and p53 mutations participate in the early stageo fg astric carcinogenesis. Increased hTERTe xpression and strong telomerase activity confer cellular immortality in amajority of gastric cancers. Am-plification and overexpression of the c-met,t he EGF receptor(EGFR) andthe cyclin Egenes areassociated with the late stage. Overexpression of growth factors and angiogenic factors lead to cancer progression and metastasis. Some of these changes occur often in well differentiated and in poorly differentiated typeso f cancers and some differ by histological type or (gastric or intestinal) mucin phenotype.I ntestinal metaplasia and adenomas sharea bnormalitiess imilar to those in the well-differentiated type of gastric cancer, sucha st he APC and K-ras mutation albeit at low frequency.
GROWTH FACTORS, CYTOKINES, ANGIOGENIC FACTORS
Gastric cancer cells produce various growth factors and express their receptors to bring about biological events, includingc ancer-stromal interactions (2, 4). Thesef actors inducen ot only cell growthb ut also extracellular matrixd egradationa nd angiogenesis which facilitate tumour invasion and metastasis. Simultaneous expression of EGF/TGF-alpha and EGFR is associated with cancer progression and correlates with poor patient prognosis. IL-alpha acts as an autocrine growth factor of gastric cancerand it interacts with the EGFR system. Gene amplification of the c-met (hepatocyte growth factor [HGF])receptor frequently occurs in the scirrhous type of gastric cancer. HGF produced by stromal cells stimulates cancer cell motility.G ene amplification and overexpression of HER-2/c-erbB2 and K-sam arepreferentially found in well differentiated and poorly differentiated gastric cancer,respectively.
Angiogenesis is regulated by severala ngiogenic factors produced by cancer cells and stromal cells (4). Neovascularisation stimulates the growth of the primary tumour and provides an avenue for haematogenousm etastasis. In gastric cancer,t herei sap ositive associationb etween microvessel count, metastaticp otential and poor prognosis. Among the best known angiogenic factors of gastric cancer cells are vascular endothelial growth factor (VEGF), interleukin (IL-8),b asic fibroblast growth factor (bFGF) and platelet-derived endothelial cell growth factor (PD-ECGF). Most gastricc ancers express IL-8/receptor systems, and IL-8 levels correlate closely with neovascularity.W ell differentiated gastric cancer expresses VEGF at high levels, while poorly differentiated scirrhous cancer expresses strongly bFGF.
CELL CYCLE REGULATORS
Cell cycle checkpoints arer egulatory pathway that control cell cycle transitions, and ensureD NA replication and chromosome segregation with high fidelity.Any dysbalance in the actions of cell cycle regulators results in genomic instability and unbridled cell proliferation and will contribute to tumour development (2, 4). Several abnormalities of positive and negative regulators of the cell cycle area ssociated with gastric cancer.Gene amplification of cyclin Eis present in 15-20% of gastric cancer samples and an increased expression of cyclin Ec orrelates with tumour progression. p53 is multifunctional and participatesi nc ell cycle regulation in part through p21 induction. Inactivation of p53 by loss of heterozygosity (LOH) and through mutations occurs in over 60% of all gastric cancers. Expression of p27 is reduced in gastricadenoma, and further reduction is associated with metastasis, indicating participation in development as well as in progression of gastric cancer.Aberrant (reduced or increased) expression of p16 is frequently found in gastric cancer, but the biological role is unknown. An important downsteam target for cyclins/cyclin-dependent kinases (CDKs) at the G1/S checkpoint is ther etinoblastoma (RB) protein. The expression of RB is weaker in nodal metastases of primary gastric cancers. Checkpoint kinase 1(Chk1) and Chk2 areD NA damage-activated kinases involved at the G2/M checkpoint. Both Chk1 and Chk2 are overexpressed in more than 70% of gastric cancers associated with the p53 mutation. Chk1 and Chk2 may play arole in the checkpoint function of gastric cancers with the p53 mutation.
GENETIC INSTABILITY
Genomici nstability is classified into microsatellite instability( MSI) and chromosome instability.D ysfunction of DNA mismatch repair causes MSI. The target genes for MSI include TGFBRII, IGFIIR, BAX, hMSH3, hMSH6 and MBD4 (2, 4). MSI or genetic instability leads to accumulation of genetic alterations and contributes to the pathogenesis not only of hereditary non-polyposis colorectal cancer but also of sporadic gastric cancer.CpG island hypermethylation of hMLH1 and loss of expression arethe main mechanisms of MSI in sporadic gastric cancer.T he frequency of MSI is especially high in well differentiated gastric cancerofthe foveolar phenotype with apapillary structure. Therei sat ight association between MSI and tumour multiplicity; the frequency of MSI is apparently high in patients with multiple primary cancers. Therefore, detection of MSI serves as agood predictor of another cancer in ap atient with gastric cancer.M any reports have, on the other hand, indicated that MSI is associated with less aggressive behaviour of the tumour and am oref avourable prognosis.
EPIGENETIC ALTERATIONS
Among the epigenetic alterations that occur in cancer, abnormalities of the transcription step areimportant; post-translational modifications (such as ubiquitindependent degradation) arealso involved. For regulation of gene expressiono nat ranscriptional level, DNA methylation, histone modification and chromatin remodeling function as an on-offswitch, while the transcription factorsact as avolume switch. The abnormal methylation of CpG islands -usually associated with tumour suppressor genes -l eads to transcriptional silencing, inactivation of gene function and, ultimately, to carcinogenesis (3, 4). In gastric cancer,aberrantmethylation occurs in several tumour suppressor genes, such as p16, CDH1 (E-cadherin), hMLH1, RAR-beta, RUNX3, MGMT (O 6 -methylguanine methyltransferase), TSP1 (thrombospondin-1), HLTF (helicase-like transcription factor), and RIZ1 (retinoblastoma protein-interacting zinc finger gene-1), with theincidence of methylationraging from 10% to 70%. When DNA methylation associated with 12 tumour-related genes ( hMLH1, MGMT,p 16, CDH1, RAR-beta, HLTF,R IZ1, TM, FLNs, LOX, HRASLS, HAND1)was analysed, ahigh methylation rate (5 or moremethylated genes) was observed morefrequently in stage III/IVcancers than in stage I/II cancers. Thus it indicates that DNA methylation of tumourrelated genes accumulates as the tumour progresses (7). On the other hand, some gene promoters become hypermethylated in non-neoplastic conditions, like aging. The incidence of promoter hypermethylation of hMLH1 and p16 is higher in non-neoplastic gastric mucosa of gastric cancer patients than in the gastric mucosa of healthy individuals.
The amino terminals of histones ares ubjected to acetylationa nd methylation, which recruitd ownstream regulatory factors,influence chromatin struc-ture, and arecritical determinants of transcription (3). Atight chromatin structurebyhistone deacetylation causes transcriptionalsilencing.Gastric cancer exhibits global histone hypoacetylation and, interestingly, the degree of hypoacetylation is associated with the depthoftumour invasion and with nodal metastases. Hypoacetylation of histones H3 and H4 in the p21 WAF1/Cip1 promoter region takes place in moret han ah alf of gastric cancers. Hypoacetylation of histone H3 in this promoter is associated with reduced expression of p21, regardless of p53 gene status (8). Upregulation of histone acetylationi ng astric cancer cells by treatment with trichostatinA(a histone deacetylase [HDAC] inhibitor) induces growth arrest, causes apoptosis and suppresses invasion, as the expression of p21, CBP and Bak is induced. In addition to acetylation, phosphorylationand methylation may enhance or inhibit transcription, depending on the residues affected and on the molecules that interact. Histonemodification may be atherapeutic target.
MOLECULARBASES OF GASTRIC AND INTESTINAL PHENOTYPES
In addition to classification by histology (well differentiated and poorly differentiated; intestinal and diffuse), gastric cancers may also be classified into four phenotypes by the mucin expression profile: Gtype (gastric or foveolar phenotype), I-type (intestinal phenotype), GI-t ype (intestinala nd gastric mixed phenotype) and N-type (neither gastric nor intestinal phenotype) (4, 9). The G-type is consideredtobehave morea ggressively than the I-type. Mutationso f p53 and LOH of the adenomatous polyposis coli ( APC) gene occur morefrequently in patients with the I-type than with the G-type, while MSI and alterations in the p73 gene aremorecommon in the G-typethan in theI -type. MSI in the G-type is usually associated with inactivation of hMLH1 following promoterhypermethylation. The Caudal-type homeoboxes (CDX) 1and CDX2 act as intestine-specific transcription factors and aree xpressed in I-type gastric cancers at high levels. CDX2 upregulates the expression of goblet-specific MUC2 and liver-intestine (LI) cadherin, also known as cadherin 17 ( CDH17). LI-cadherin expression is moref requently detected in I-type than G-type and is associated with tumour invasion and a poor patient prognosis. On the other hand, the expression of SOX2, am ember of transcription factor family containing an Sry-like high-mobility group box, is wellp reserved in the G-typea nd is downregulated in the I-type.
MOLECULAR EVENTSAND HELICOBACTER INFECTION
Recent studies have shed much light on the molecular mechanisms of how H. pylori infection is involved in the development of cancer in the stomach (10, 11) . Strains of H. pylori carrying the cytotoxin-associated antigen A(cagA) gene areassociated with the devel-opment of gastric cancer.T he cagA gene product, CagA, is delivered into gastric epithelial cells by the bacterial type IV secretion system; this induces morphological transformations and cell motility increases. CagA is injected and undergoes tyrosine phos-phorylationbySrc family kinases,after which it binds to SHP-2 and activates SHP-2 phosphatase. Focal adhesion kinase (FAK) is atyrosine kinase that plays a critical role in focal adhesion turnover.A ctivated SHP-2 dephosphorylates and inhibitsF AK activity. Impaired cell adhesion and increased motility by CagA may be involved in the development of gastric lesions associatedw ith H. pylori infection. Morer ecently,i th as been shown that CagA interacts with cytoplasmic domain of E-cadherin,a nd competes with beta-catenin binding; this results in accumulation of beta-catenin in both cytoplasm and nucleus. One of the important downstream targets of betacatenin signaling induced by CagA is CDX1. Forced expression of CagA in gastricepithelial cells induces MUC2 expression. Through this mechanism, CagA may cause intestinal metaplasia which predisposes to gastric cancer, especially of I-type.
GENETIC POLYMORPHISM AND CANCER RISK
An individual's cancer risk varies in line with genetic polymorphisms in the normal population since this connects directly with the person's cancer prevention. Most genetic polymorphism between individuals is due to single nucleotide polymorphisms (SNPs). Genetic polymorphism is crucial for various processesrelated to gastric carcinogenesis, including 1) the mucosal protection and inflammatory response against H. pylori infection; 2) the functioning of carcinogen detoxification and antioxidant protection; 3) the intrinsic variability of DNA repair processes; and 4) cell proliferation activity (4, 12). Variants of IL-1beta( IL1B)a nd IL-1 receptor antagonist ( IL1RN) genes, IL1B (-31Tg enotype) and IL1RN IVS 86bp VNTR (2/2 genotype) increase IL-1beta production and inhibit gastric acid secretion. This is associated with arisk of achronic hypochlorhydric response to H. pylori infection and an increased gastric cancer risk. NAT1 is responsible for N-acetyltransferase activitywhich catalyses acetylation and modification of aromatic and heterocyclic amine carcinogens. Asignificantly increased risk of gastric cancer is associated with certain genotypes of NAT1 (1088 T>A, 1095 C>A).
SNPs arepresentinthe transmembrane domain of HER-2/c-erbB2 (655 Ile >Val, A>G) and in the promoter regions of EGF (61 A/G) and MMP-9( -1562 C/T). SNPs of HER-2 and EGF significantly affect the risk of gastric cancer,w hile the genotype of MMP-9 does not; it is, however,associated with tumour invasion, metastasis and tumour stage (5). Importantly, genetic polymorphismsare also associated with therapeutic efficacy and the toxicity of anti-cancer drugs. VNTR polymorphism in the promoterr egion of the thymidylate synthasegene influences the response to 5-fluorouracil (5-FU). The number of TA repeats in the promoter region of the UDP-glucuronosyltrans-ferase 1A1 gene affects the degree of toxicity during irinotecan therapy.
SEARCH FOR NOVEL GENES INVOLVED IN GASTRIC CARCINOGENESIS
Thus, gastric cancer is accompanied by several genetic and epigenetic alterations: mutations,gene amplifications, LOH, gene silencings by DNA methylation and losses of imprinting. All of these alterations modify gene expression. Therefore, genome-wide studies of gene expression aree xtremely important for studying the precise mechanisms of cancer emergence and progression. In addition to the microarray technique, the Serial Analysis of Gene Expression (SAGE) technique is apowerful tool to allow genomewide, quantitative analysis of gene expression with high reproducibility (6). Fig. 2s hows as trategy of clinical applications of SAGE with regardtodiagnostics, treatmentand prevention.
We have created the largest SAGE library of gastric cancer in the world. It containsatotal of 137,706 expressed tags including 38,903 unique tags (GEO accession number GSE 545) ( Internet address: http://www. ncbi.nlm.nih.gov/SAGE/) (4, 13). The library is built on 5s amples of gastric cancer with different histology and stage. We have found that APOC1, CEACAM6, and YF13H12 areoften overexpressed in gastric cancer,while FUS, CDH17, COL1A1, COL1A2, and APOE areassociated with tumour progression according to studies wherewehave compared SAGE libraries between gastric cancers and healthy gastric mucosa in combination with quantitative RT-PCR. Tumours that are LI-cadherin ( CDH17)-positive by immunostaining areoften diagnosed only at alate stage, and the prognosis of patients with LI-cadherin-positive tumours is worse than with negative tumours.
In as earch for gastric cancer-specific genes, we compared gastric cancer SAGE libraries with various healthy tissues of crucial organsi nt he SAGE-map database, and identified 54 candidateg enes (14) . Quantitative RT-PCR analysis revealed that APIN, TRAG3, CYP2W1, MIA, MMP-10, DKK4, GW112, REGIV,a nd HORMAD1 aree xpressed much more strongly in gastric cancers than in healthy samples of 14 crucial organs. Immunostaining of MIA (melanoma inhibitory activity) and MMP-10 correlatedw ith apoor prognosis in patientswho had advanced gastric cancer. According to enzyme-linked immunosorbent assay (ELISA) therewerehigh levels of MMP-10 in most serum samples (95%) from patients with gastric cancer. MIA-transfected gastric cancer cells were up to three times moreinvasive than cells transfected with empty vector.Therefore, MMP-10 is ag ood serummarker for gastric cancer,while MIA and MMP- 10 arep rognostic factors for gastric cancerp atients. Since expression of MIA and MMP-10 is so closely restricted in cancer,t hese two molecules might also turno ut to be good and nontoxic therapeutic targets.
Regenerating islet-derived family member 4( Re-gIV) belongs to asuperfamily of calcium-dependent lectins. RegIV-positive tissue is associated with the intestinal mucin phenotype as well as with neuroendocrine differentiation of gastriccancer (15) . RegIV is also expressed in colorectal carcinomas, carcinoids and pancreatic cancers, but not in lung and breast cancers. High and specific levels of RegIV ared etected in 36% of serum samples by ELISAfromg astric cancerpatients. In vitro studies with RegIV-transfected cells have shown that RegIV inhibits 5-FU induced apoptosis through induction of EGFR phosphorylation and inhibition of caspase-3a nd -9. Expression of RegIV is strongly associated with resistance to combination chemotherapy with 5-FU and cisplatin. These findings suggest that RegIV may serve as an ovel biomarker and an indicator of chemoresistance of gastric cancer.
In an effort to search for novel tumour suppressor genes in gastric cancer,g enes with ad ecreased expression in gastric cancer tissue weres creened by SAGE data analysis and RT PCR; CLDN18 (encoding claudin-18) was down-regulated in gastricc ancer (16) . The claudin protein family comprises 24 members (claudin-1toclaudin-24) that areimportant components of tight junction strands in polarised epithelial cells, including gastric epithelia. Expression of claudin-18 is reduced in some instances of intestinal metaplasia, and many gastric adenomas and carcinomas ( Fig.3) . Downregulation of claudin-18 was cor-related with poor survival in advanced gastric cancers. Down-regulation of claudin-18was observed in over7 0% of gastric cancers with intestinal mucin phenotype. Downregulation of claudin-18 may be an early event in gastric carcinogenesis and constitutes also a good marker of poor survival of gastric cancer patients. SAGE-based analyses thus provide alist of candidate genes that areinvolved in gastric carcinogenesis and may serve as novel diagnostic markers and therapeutic targets in our strive to combat gastric cancer.
CONCLUSION
Molecularevents during gastric carcinogenesis and a searchf or novelg enes through global analysis of gene expressionweredescribed. Advances in our understanding the genetic and molecular bases of cancer lead to new diagnosisa nd therapy.D ecision of cancer treatment may be guided by the molecular attributes of the individual patient.Itissaid that cancer treatment gets personal (17) .
